Blackhall, K; Appleton, S; Cates, CJ; (2003) Ionisers for chronic asthma. The Cochrane database of systematic reviews, 3 (3). CD002986-. ISSN 1469-493X DOI: https://doi.org/10.1002/14651858.CD002986

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/9019/

DOI: https://doi.org/10.1002/14651858.CD002986

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the author(s)
**Table of Contents**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Background</td>
<td>2</td>
</tr>
<tr>
<td>Objectives</td>
<td>2</td>
</tr>
<tr>
<td>Methods</td>
<td>2</td>
</tr>
<tr>
<td>Results</td>
<td>4</td>
</tr>
<tr>
<td>Discussion</td>
<td>6</td>
</tr>
<tr>
<td>Authors' Conclusions</td>
<td>7</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>7</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>8</td>
</tr>
<tr>
<td>Data and Analyses</td>
<td>15</td>
</tr>
</tbody>
</table>

- Analysis 1.1. Comparison 1 Negative ionised air versus non-ionised air, Outcome 1 FEV1 (Fall %) after exercise test. 16
- Analysis 1.2. Comparison 1 Negative ionised air versus non-ionised air, Outcome 2 Baseline FEV1 (litres) (after inhalation of negative ions prior to exercise testing). 17
- Analysis 1.3. Comparison 1 Negative ionised air versus non-ionised air, Outcome 3 Morning Peak Expiratory Flow (Litres/min). 17
- Analysis 1.4. Comparison 1 Negative ionised air versus non-ionised air, Outcome 4 FEV1 (Litres/min) > 4 weeks. 18
- Analysis 1.5. Comparison 1 Negative ionised air versus non-ionised air, Outcome 5 Evening Peak Expiratory Flow (Litres/min). 18
- Analysis 1.6. Comparison 1 Negative ionised air versus non-ionised air, Outcome 6 FEV1 (Fall %) after histamine challenge. 19
- Analysis 1.7. Comparison 1 Negative ionised air versus non-ionised air, Outcome 7 Asthma Symptom Score 1. 19
- Analysis 1.8. Comparison 1 Negative ionised air versus non-ionised air, Outcome 8 Asthma Symptom Score 2. 20
- Analysis 1.9. Comparison 1 Negative ionised air versus non-ionised air, Outcome 9 Bronchodilator use. 21
- Analysis 1.10. Comparison 1 Negative ionised air versus non-ionised air, Outcome 10 Morning PEFR (First arm change score). 21
- Analysis 2.1. Comparison 2 Positive ionised air versus non-ionised air, Outcome 1 FEV1 (Fall %) after exercise test. 22
- Analysis 2.2. Comparison 2 Positive ionised air versus non-ionised air, Outcome 2 Baseline FEV1 (litres) (after inhalation of positive ions prior to exercise testing). 22

What's New                                                                 | 22   |
| History                                                                 | 23   |
| Contributions of Authors                                               | 23   |
| Declarations of Interest                                               | 23   |
| Sources of Support                                                     | 23   |
| Index Terms                                                            | 24   |

Ionisers for chronic asthma (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ionisers for chronic asthma

Karen Blackhall¹, Sarah Appleton², Christopher J Cates³

¹Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, London, UK. ²Department of Medicine, The Queen Elizabeth Hospital, Adelaide, Australia. ³Community Health Sciences, St George’s, University of London, London, UK

Contact address: Karen Blackhall, Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. karen.blackhall@lshtm.ac.uk.

Editorial group: Cochrane Airways Group.

Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 2, 2010.

Review content assessed as up-to-date: 18 January 2010.

Citation: Blackhall K, Appleton S, Cates CJ. Ionisers for chronic asthma. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002986. DOI: 10.1002/14651858.CD002986.

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Previous reports have shown that ion content in the air may have an effect on respiratory function. Results from studies which test the efficacy of air ionisers to reduce asthma symptoms are often inconclusive and their use as a treatment for asthma remains debatable.

Objectives

We conducted a systematic review of the available evidence to determine the effectiveness of positive and negative ion generators in people with asthma.

Search methods

We searched the Cochrane Airways Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) as well as the alternative medicine database AMED. Searches were current as of January 2010.

Selection criteria

Randomised controlled trials (parallel or crossover design studies) comparing ionisers with dummy ionisers (being negative or positive ion emitters), in children or adults with chronic asthma.

Data collection and analysis

Two reviewers independently assessed titles and abstracts of studies and assessed trial quality. Study quality was determined using two methods: The Cochrane approach to allocation concealment and the five point Jadad scale.

Main results

Six studies were selected for inclusion (106 participants). No results were combined as the studies were all of a crossover design.

EFFECTS OF NEGATIVE ION GENERATORS (five studies)

No study reported a significant difference in lung function between ionised and control air (morning Peak expiratory flow (PEF) - three studies; forced expiratory flow in one second (FEV1) - one study). There were no significant differences in symptoms or beta-2 agonist usage between ionised and control air in three studies.

EFFECTS OF POSITIVE ION GENERATORS (one study)

This study demonstrated that although positively ionised air was associated with a larger fall in FEV1 with exercise, this did not reach statistical significance. Baseline FEV1 was not demonstrated to be significantly different between treatment groups.
Authors’ conclusions

Based on the evidence currently available from randomised controlled trials, a recommendation cannot be given for the use of room air ionisers to reduce symptoms in patients with chronic asthma.

Plain Language Summary

Ionisers for chronic asthma

Ion generators have been marketed for use in homes to remove dust and smoke particles in order to improve symptoms in people with asthma. Although complex laboratory studies show that ion generators alter airways function, the few studies which have been conducted in the homes of people with asthma, demonstrate no significant benefit in improving lung function or symptoms.

Background

Asthma is a chronic pulmonary disorder which affects an estimated 3.4 million people in the UK (ONS 1996). A recent National Asthma Campaign survey (Smith 2000) suggests that 42% of those who have asthma face significant challenges in their daily lives due to their condition. Two thirds of the asthma population are said to be receiving inhaled steroids with many expressing concerns about the long-term effects of their medication (Smith 2000). Although pharmacological interventions continue to improve, the prevalence of asthma remains high (ONS 1996). Such concerns highlight the need for further investigation into the benefits of non-pharmacological treatment in order to compliment pharmacological therapies.

Previous reports have shown that alteration of ions in the air may have an effect on respiratory function (Wheiner 1969). As a result, interest has grown in the physiological effects of positive and negative air ions in people with asthma. With the development of ion generators it has become possible to artificially manipulate the ion concentration in air. Studies (Nogrady 1983; Lipin 1984; Warner 1993) have been carried out to test the efficacy of air ionisers in order to reduce air-borne allergens and smoke particles, with a view to alleviating asthma symptoms. Results of such studies are often inconclusive and the effectiveness of air ionisers as a treatment for asthma remains debatable. This systematic review of the available evidence was conducted in order to summarise the results of all identified randomised controlled trials comparing ionisers to placebo.

Objectives

To determine whether air ionisers (positive or negative ion emitters) are effective in relieving symptoms and improving respiratory function in people with chronic asthma.

Methods

Criteria for considering studies for this review

Types of studies
Randomised controlled trials (parallel or crossover design studies).

 Types of participants
We included studies assessing children and adults with chronic asthma.

 Types of interventions
Inhalation of positively or negatively ionised air, generated by an ioniser in the home or laboratory setting. The comparative group will have inhaled non-ionised air through a dummy ioniser.

 Types of outcome measures
Primary outcomes
1. Respiratory physiological measures: Peak Expiratory Flow (PEF) and Forced Expiratory Volume in one second (FEV1)
2. Asthma symptom scores
Secondary outcomes

1. Health-related Quality of Life
2. Exacerbation
3. Provocation tests (e.g. exercise, histamine)
4. Bronchodilator usage
5. Inhaled corticosteroids usage

Search methods for identification of studies

Trials were identified using the Cochrane Airways Group Specialised Register of trials which is derived from systematic searching of electronic databases including CENTRAL, MEDLINE, EMBASE and CINAHL, and hand-searching of respiratory journals and meeting abstracts. All records in the Specialised Register coded as 'asthma' were searched using the following terms: (ionis* or ioniz* or "electrostatic precipitator")

The Cochrane Central Register of Controlled Trials (CENTRAL) was searched using the same terms. Additional searching was carried out on the alternative medicine database AMED (1985 - present) using the search:

#1 exp ASTHMA/
#2 asthma$ or wheez$
#3 1 or 2
#4 exp IONS/
#5 (ionis$ or ioniz$).tw.
#6 electrostatic$.tw.
#7 4 or 5 or 6
#8 3 and 7

Searches were current as of January 2010.

Data collection and analysis

Selection of studies

Two reviewers (KB and SLA) independently assessed titles and abstracts of studies, identified by the database search, and selected studies for inclusion in the review. We also independently assessed the full text of all selected abstracts for suitability for inclusion in the review.

Data extraction and management

We extracted data independently from the eligible studies. Disagreement was resolved by consensus.

Assessment of risk of bias in included studies

We independently determined study quality using two methods:

1. The Cochrane approach to allocation concealment using the following grading system:
   - Grade A: Adequate concealment
   - Grade B: Uncertain
   - Grade C: Inadequate concealment
   - Grade D: allocation concealment not used
2. The five point Jadad scale (Jadad 1996) according to the following criteria:
   - (a) Study described as randomised (yes: 1, no: 0)
   - (b) Method of randomisation described and appropriate (yes: 1, no: -1)
   - (c) Study described as double blind (yes: 1, no: 0)
   - (d) Method of blinding described and appropriate (yes: 1, no: -1)
   - (e) There was a description of withdrawals and drop outs (yes: 1, no: 0)

Data were extracted independently by both reviewers and authors of trial reports were contacted for extra or missing information. We resolved any disagreement between reviewers by discussion.

Data synthesis

Due to the crossover design employed in the studies, we could not reliably pool data from the individual studies in RevMan, and individual study data only is shown in the Forest plots. We extracted first arm data for Nogrady 1983 and analysed this based upon individual patient scores. We reported data for outcomes in the crossover trials in the text of the review.

If parallel group data are available in future versions of this review, we will report pooled analyses as weighted mean differences (WMD) and standardised mean differences (SMD) depending upon the availability of data measured on the same or different metrics. If we can obtain suitable paired data for crossover studies, we will combine this using inverse variance meta-analysis. Where a more positive outcome is favourable, (e.g. PEF) data, we entered this as positive values. In this case the titles of the horizontal axes have been reversed so that effects that favour the treatment under review move to the right. We have graphed continuous outcomes for which lower scores imply improvement (e.g. symptom scores and percentage reduction in FEV1 as a measure of bronchial reactivity) according to standard Cochrane graphical convention such that effects that favour the treatment under review move to the left.

The following data were entered separately on the basis of:

1. charge of ion emission, i.e. positive versus negative ions;
2. duration of exposure to ionised air.

Subgroup analysis and investigation of heterogeneity

We performed a subgroup analysis on the basis of age group of participants (adults versus children)
RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.

Results of the search
We identified 22 abstracts from the original search, nine of which were not trials. Thirteen full text articles were obtained. Two studies were excluded because they were not randomised (Kirkham 1984; Osterballe 1979) one was excluded because it was neither randomised nor controlled (Jones 1976) and two studies were not suitably controlled (Palit 1966; Zylberberg 1960) One study determined the effect of ionisers on airborne particles but recorded no patient outcomes (Wickman 1989) and one study reported previously published data (Nogrady 1983). A total of six studies were included in this review. An update search conducted in January 2010 did not identify any additional relevant studies.

Included studies
See Characteristics of included studies for details of individual studies.
We included six studies in this review, all of which utilised a crossover design. The review includes studies conducted between 1983 and 1994 two studies from Israel (Ben-Dov 1983; Lipin 1984) and four studies conducted in Australia (Nogrady 1983), UK (Warner 1993) and Denmark (Daugbjerg 1988; Larsen 1994). Two studies were published in Danish and were translated into English (Daugbjerg 1988; Larsen 1994). The remaining studies were all published in English.

Study design
All studies were randomised. One was single-blind (Daugbjerg 1988). The remaining studies were double-blind (Ben-Dov 1983; Larsen 1994; Lipin 1984; Nogrady 1983; Warner 1993). No information on methods of randomisation were reported. Larsen 1994 provided details on the method of randomisation upon request.

Participants
Sixty eight children participated in four studies (Ben-Dov 1983 (n = 17); Lipin 1984 (n = 12); Daugbjerg 1988 (n = 19); Warner 1993 (n = 20)) with an age range of eight months to 20 years. There were 40 adults who participated in two studies (Nogrady 1983 (n = 20); Larsen 1994 (n = 20)), with a mean age of 36 to 47 years.

Diagnosis and severity of asthma were not described in the studies. Ben-Dov 1983 and Lipin 1984 recruited participants known to have had asthma attacks provoked by exercise challenge. Daugbjerg 1988 did not report how a diagnosis of asthma was reached and no baseline data on symptoms were reported. Larsen 1994 recruited participants with an observed variation in peak flow of >20% or reversibility of over 15% in FEV1 after inhalation of 0.2 mg of salbutamol, were treated with ≤ 1000 mcg inhaled steroids per day and required bronchodilators on a daily basis. Nogrady 1983 made a clinical assessment for asthma at the outset of the study, including PEFR and allergen sensitivity. No other details of clinical examination were reported. Warner 1993 recruited children described as suffering from perennial asthma.

Interventions
Negatively ionised air was used in four home-based studies (Daugbjerg 1988; Larsen 1994; Nogrady 1983; Warner 1993) and one laboratory based study (Ben-Dov 1983). Positively ionised air was used in one laboratory based study (Lipin 1984). Nogrady 1983 exposed participants to 150,000 negative ions/ml at night for 10 hours during the 8 week active treatment period. Daugbjerg 1988 exposed participants to 220,000 negative ions per cm3 or placebo for either eight and then four weeks or four and then eight weeks treatment. In Larsen 1994 and Warner 1993 the ion count was not reported. In both studies participants were exposed to an ioniser during the day in the living room and at night in the bedroom for a treatment period of four weeks (Larsen 1994) and six weeks (Warner 1993). Ben-Dov 1983 exposed participants to negatively charged ions (0.5 to 1.0 x 106 ions per cm3 for approximately 45 minutes) and conducted identical six minute exercise provocation tests (cycle ergometry) where each challenge was undertaken twice (3 to 24 hours apart) with active and placebo ionisers. Participants were also exposed to 4 to 5 x 105 negative ions per cm3 during histamine provocation, with doubling concentrations of histamine to a maximum of 10 mg/ml until a 20% drop in FEV1 was obtained compared to baseline values. Each challenge was undertaken twice (24 hours apart) with active and placebo ionisers. Lipin 1984 exposed participants to positively charged ions (0.5 to 1.0 x 106 ions per cm3) and conducted identical six minute exercise provocation tests (cycle ergometry) where each challenge was undertaken twice (24 hours apart) with and without exposure to the active ioniser.

Outcome measures
There was variation in the overall outcomes used across the six studies. The studies conducted under laboratory conditions measured lung function and did not assess symptoms or medication usage (Ben-Dov 1983; Lipin 1984)
Of the remaining studies, assessments were conducted of lung function in three studies (Larsen 1994; Nogrady 1983 and Warner 1993); symptoms were assessed in three studies (Daugbjerg 1988; Larsen 1994 and Warner 1993) and attempts to record medication usage were made in two studies (Daugbjerg 1988; Warner 1993). One study (Nogrady 1983) reported data with significant differences in baseline measurements (approximately 100 ml difference in PEF) between the two comparison groups possibly due to the gender distribution which is suggestive of unsuccessful randomisation. Results were presented in the form of the two groups, according to whether participants were exposed to the active ioniser or the placebo ioniser first. Data from each group were analysed separately and intra-group comparisons were made between the active and placebo periods. A second publication of the trial contributed no extra data to the review so is listed in ‘excluded studies’.

Data from another study (Daugbjerg 1988) does not appear in the table of comparisons as the data were not usable due to the use of non-validated symptom scoring.

**Risk of bias in included studies**

Overall, the included papers were of strong study design. All studies were conducted double-blind, except the Daugbjerg study (Daugbjerg 1988) which was single blind. The order of the treatments within the crossover were described as randomised but randomisation methods were not stated. However, none of the studies commented on the number of participants excluded from the trials or reported a power calculation to determine sample size. Withdrawals and drop-outs were adequately described.

The sample sizes of each of the six studies were small, ranging from 12 to 20 participants. The total number of participants contributing data from all six studies was 106. A wash-out period between treatment arms of two weeks was reported in only one study (Nogrady 1983). Although the duration of exposure in the laboratory studies was short, it is unknown whether a wash-out period of greater than 3 to 24 hours would be required.

Inclusion/exclusion criteria were not formally specified. Inclusion criteria was specified in two studies, with respect to a definition of stable asthma (Larsen 1994), and a concentration of house dust mite allergen Der p1 (Warner 1993). The two laboratory based studies reported a general statement of inclusion of subjects as those being “known to have had asthmatic attacks provoked by physical exertion”. Only one study specified exclusion criteria relating to medication use (Larsen 1994).

There was total agreement between two independent assessments of study quality using the Cochrane approach and the Jadad scale. All five studies were graded B according to the Cochrane approach to concealment of allocation as none described the method of concealment of allocation. This is not a major concern if the blinding of participants and assessors was secure. No further details were provided by the authors, about methods of concealment or randomisation, which increased the allocated scores of the included trials. All studies were given a Jadad score of 3.

**Effects of interventions**

**EFFECTS OF NEGATIVE ION GENERATORS**

**Respiratory physiological measures**

**Peak Expiratory Flow**

Morning PEF

Two studies with adult participants (Nogrady 1983; Larsen 1994) did not report significant differences between the exposure periods.

One study conducted in children (Warner 1993) reported no significant difference.

Evening PEF

No statistically significant differences were reported for evening PEF (Nogrady 1983; Warner 1993; Larsen 1994). No values were presented in the papers.

**Forced Expiratory Volume in one second**

**Baseline FEV1**

Only one study, which was a laboratory based study in children (Ben-Dov 1983) measured FEV1 after 10 minutes inhalation of control and negatively ionised air, but prior to exercise testing. No significant differences were demonstrated in “Baseline” FEV1 between the treatment groups.

(ii) Percentage fall in FEV1 after exercise provocation

Ben-Dov 1983 demonstrated no significant difference in percentage reduction in FEV1 from baseline after exercise provocation in the ionised air exposed group compared to those exposed to control air.

(iii) Percentage fall in FEV1 after histamine provocation

Ben-Dov 1983 demonstrated no significant difference in percentage reduction in FEV1 from baseline after histamine provocation in the ionised air exposed group compared to those exposed to control air.

(iv) Absolute FEV1

Only one study, which was a home based study in adults (Larsen 1994) measured FEV1 after four weeks exposure to control and negatively ionised air. This study determined there was no significant difference in absolute FEV1 (litres) between treatments.
Asthma symptom scores

Three studies, one conducted in children (Warner 1993) and two in adults (Nogrady 1983; Larsen 1994) recorded asthma symptoms. The Warner study utilised a different symptom scale while the Nogrady and Larsen studies used the same. These measured five dimensions of symptoms and reported a mean symptom score only, not scores for the individual dimensions including the "Total" dimension. Of these three studies, only the Larsen study reported a "Total" dimension. Thus it was not possible to pool these data in an analysis using a standardised mean difference and the analyses are reported separately according to the use of Asthma Symptom Scale "1" and Asthma Symptom Scale "2".

Using the Asthma Symptom Score "1" (Warner 1993) there were no significant differences between the treatments. After six weeks exposure to both ionised air and control air, in the symptom dimensions of "nighttime wheeze"; "daytime wheeze"; "nighttime cough" and "daytime activity".

Using the Asthma Symptom Score "2" (Larsen 1994) there were no significant differences between the treatments, after four weeks exposure to both ionised and control air, in the symptom dimensions scores of: "total"; "sleep disturbance"; "wheeze"; "activity level"; "coughing" and "sputum production".

Nogrady 1983 also used this scale, however, the authors reported a mean of all five dimensions only. There was no significant difference between exposure periods in the mean symptom score.

Bronchodilator Use

Three studies recorded participants' asthma medication use (inhaled or oral bronchodilators, corticosteroids, sodium cromoglycate and other medications) (Nogrady 1983; Warner 1993; Larsen 1994). No study reported a significant difference in favour of ionised air versus control.

EFFECTS OF POSITIVE ION GENERATORS

Only one study measured the effects of positive ions on lung function. This study (Lipin 1984), conducted in children demonstrated that positively ionised air was associated with bronchoconstriction, measured by the maximum fall in FEV1 after exercise from baseline (after 10 minutes exposure to ionised air but before cycling) between treatment groups. The confidence interval of the effect of positive ionisation on FEV1 after exercise includes no difference and also a clinically significant deterioration, but the sample size is too small to draw any firm conclusion. Baseline FEV1 was also demonstrated not to be significantly different between treatment groups.

DISCUSSION

Ion generators have been marketed for use to reverse negative ion depletion and to remove dust and smoke particles by electrostatic precipitation. There is a paucity of data in the literature generated from randomised controlled trials of the effects of ion generators for chronic asthma. Consequently this review has been limited by the small numbers of studies eligible for inclusion in the review and also the inconsistent use of outcome of measures. It is possible that the studies lacked the statistical power to detect changes in outcomes because of the small sample sizes of these studies, ranging from 12 to 20.

The five studies of the effects of negative ion generators and the one study of the effect of a positive ion generator included in this review have failed generally to demonstrate any benefit of these instruments for the treatment of chronic asthma in children and adults. Relevant outcome measures such as PEF, FEV1 after exercise and histamine provocation, symptom scores and asthma medication showed no significant improvement after extended periods of exposure to charged ions compared to normal/control air. It is important to note however that the Ben-Dov et al study (Ben-Dov 1983), a laboratory based study in children demonstrated that during the active ionisation period, the FEV1 after exercise provocation fell 8% less than that during the control air period. This reduction in bronchial reactivity was statistically significant using the Student’s paired t-test with a P value of less than 0.015. This reflects the power inherent in a paired t-test, compared to the use of a mean difference. The clinical relevance of this finding generated in a controlled laboratory setting with the concentration of ions at the mouthpiece 100 times the natural concentration in the air is unclear. Furthermore, a statistically significant reduction in bronchial reactivity after histamine challenge did not occur. Interestingly, four of nine participants demonstrated greater histamine sensitivity during inhalation of negative ions compared to control air.

The study by Lipin et al (Lipin 1984) also demonstrated a statistically significant increase in bronchial reactivity after exercise in participants during inhalation of positive ions (P = 0.04). In this study, eight of twelve children experienced a greater reduction in FEV1 when the active ioniser was used compared to the placebo ioniser. Two showed no change and two showed a reduction in reactivity. All other outcomes in this review were statistically consistent with those reported by authors of the studies.

Asthma symptoms were not demonstrably improved as a con-
sequence of active ionisation. The two studies, however, which
recorded or reported this outcome used two apparently un vali-
dated symptom scales; the Nogrady study (Nogrady 1983) which
utilised the same scale as the Larsen study (Larsen 1994) reported a
mean symptom score of the five dimensions rather than the "Total"
dimension score. The frequency of "nighttime cough" recorded in
the Warner study (Warner 1993) increased during the ionisation
period (exposure to negative ions for six weeks) to a level which
approached statistical significance [Wilcoxon signed rank sum test
P = 0.055]. If the use of room air ionisers is to be pursued then
this finding requires further investigation.

Asthma medication use was not demonstrated to be significantly
reduced during active ionisation compared to when the placebo
ioniser was in use. Beta-2 agonist use was an outcome measure
in only one of three studies which recorded medication use. The
amount of rescue medication used is more likely to reflect a change
in condition as compared to other asthma medications.

One study (Larsen 1994) provoked some interesting correspon-
dence (Jonassen 1996) which suggests the need to carry out initial
trials on the efficiency of the ioniser before using it in a trial. The
ioniser is an instrumental component in the trial and could potent-
ially influence the trial outcome. Another point about the length
of time an ioniser should be turned on in order to ‘clean’ the air
in a room is also worthy of consideration. Any trials implemented
to test an improvement of symptoms in asthma patients should
consider these points.

In conclusion, individual studies in a laboratory setting suggest
that positively ionised air may aggravate exercise induced asthma
and negatively ionised air may attenuate exercise induced asthma
during exposure to these charged ions at 100 fold the concentration
found naturally in the air. No other significant benefit or harm
in terms of lung function (baseline and absolute FEV1, PEF),
asthma symptoms or medication use were demonstrated and none
occurred in the home setting.

AUTHORS’ CONCLUSIONS

Implications for practice

Based on the evidence currently available from randomised con-
trolled trials, a recommendation cannot be given for the use of
room air ionisers in the homes of patients with chronic asthma.

Implications for research

The strength of evidence from six randomised controlled trials
does not suggest that air ionisers are significantly beneficial for
patients with chronic asthma. There are no further data to provide
additional evidence to support their use and the absence of such
data in the medical literature since 1993 suggests a declining in-
terest. The review does suggest, however, that further trials would
need to incorporate issues on compliance, efficiency of the ioniser
and the environment in which the trial takes place.

ACKNOWLEDGEMENTS

Thanks to Jane Dennis for her very thorough and accurate transla-
tions. Thanks to Toby Lasserson for his support. We gratefully ac-
knowledge the assistance of Vasya Vlassov for helping with trans-
lating from Russian.

REFERENCES

References to studies included in this review

Ben-Dov 1983 [published data only]
Ben-Dov I, Amirav I, Shochina M, Amitai I, Bar-Yishay E,
Godfrey S. Effect of negative ionisation of inspired air on
the response of asthmatic children to exercise and inhaled
83302921]

Daugbjerg 1988 [published data only]
Daugbjerg P, Brenoe E, Henriksen E, Ibsen KK. Ion
generator and asthmatic bronchitis/bronchial asthma.
Evaluation of an ion generator in the treatment of recurrent
asthmatic bronchitis and bronchial asthma [Iongenerator
og astmatisk bronchitis/astma bronchiale. Evauering
af iongenerator i behandling af recidiverende astmatisk
bronchitis og astma bronchiale hos børn]. Ugeskrift

Larsen 1994 [published data only]
Larsen KR, Olsen OT, Jarnvig IL, Svendsen UG. Ion
generators and bronchial asthma. A double-blind placebo
controlled study [Iongeneratore og asthma bronchiale. En
dobbeltblind placebokontrolleret undersøgelse]. Ugeskrift

Lipin 1984 [published data only]
Lipin I, Gur I, Amitai Y, Amirav I, Godfrey S. Effect
of positive ionisation of inspired air on the response of

Nogrady 1983 [published data only]
Nogrady S. Air ionisation-its effects in bronchial asthma.
Australia and New Zealand Journal of Medicine 1983;13(5):
547.
* Nogrady SG, Furness SB. Ionisers in the management of

Ionisers for chronic asthma (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
References to studies excluded from this review

Jones 1976 [published data only]

Kirkham 1984 [published data only]

Mitchell 1980 [published data only]
Mitchell EA, Elliott RB. Controlled trial of an electrostatic precipitator in childhood asthma. Lancet 1980;2(8194):559–61.

Nogrady 1983b [published data only]

Osterballe 1979 [published data only]

Palti 1966 [published data only]

Ponomarenko 2003 [published data only]

Zylberberg 1960 [published data only]

Additional references

Ball 1980

Dantzler 1983

Gnecchi Ruscone 1985

Jonassen 1996

ONS 1996

Podleski 1980

Posse 1975

Smith 2000
Smith NM [on behalf of the National Asthma Campaign]. The ’needs of people with asthma’ survey and initial presentation of the data. Asthma Journal 2000;5:135–7.
## Characteristics of included studies

**Ben-Dov 1983**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Crossover study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomisation method:</td>
<td>unclear</td>
</tr>
<tr>
<td>Blinding:</td>
<td>Double-Blind</td>
</tr>
<tr>
<td>Excluded:</td>
<td>not described</td>
</tr>
<tr>
<td>Withdrawals:</td>
<td>None stated</td>
</tr>
<tr>
<td>Baseline characteristics:</td>
<td>comparable</td>
</tr>
<tr>
<td>Power calculation:</td>
<td>not given</td>
</tr>
<tr>
<td>Jadad Score:</td>
<td>3</td>
</tr>
</tbody>
</table>

| Participants                   | Total = 17 children with asthma  |
|                                | (17 completing trial)            |
| Gender-11M:6F. Age range 10-20 years, mean age 12.5 years | All patients had exercise-induced asthma |
| Inclusion/exclusion criteria-  | not stated                      |
| 11 exercised challenged        | 10 histamine challenged         |
| (4 participated in both)       | No details of severity reported |

| Interventions                  | Laboratory-based study:         |
|                                | Negatively ionised air (4x10/5-10x10/5 ions /cm3) versus |
|                                | Control room or non-ionised air. |
|                                | 10 minutes pre-challenge (exercise and histamine) exposure, 6 minutes exercise test 3-24 hours apart. 3 minutes post-histamine challenge measurement. |
|                                | Histamine provocative dose = PD20 |

| Outcomes                       | FEV1 measurement pre-challenge, during challenge and post-challenge |

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>Information not available</td>
</tr>
</tbody>
</table>
### Daugbjerg 1988

**Methods**
- Crossover study
- Randomisation method: unclear
- Blinding: single blind
- Excluded: not described
- Withdrawals: 3
- No baseline statistics given
- Power calculation: not given
- Jadad score: 3

**Participants**
- Total = 19 children (16 completing trial)
- Gender: 12m:7F (9m:7F completing)
- Average age 63 months
- No baseline measurements taken
- All patients had asthma or ‘Wheezy Bronchitis’
- Inclusion/exclusion criteria-not stated
- No details of severity reported.

**Interventions**
- Home-based study: negatively ionised air versus control/non-ionised air
  - 3 x 4-week periods

**Outcomes**
- In house developed four point symptom score; medication usage; parent reported school absence/days of sickness

**Notes**
- Results not usable

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>Information not available</td>
</tr>
</tbody>
</table>

### Larsen 1994

**Methods**
- Crossover study
- Randomisation method: Third party drew ‘active’ or ‘placebo’ labels out of an envelope (personal communication from trialist).
- Blinding: Double-blind
- Excluded: not stated
- Withdrawals: 1
- Baseline characteristics: comparable
- Power calculation: not given
- Jadad score: 5

**Participants**
- Total = 20 adults (19 completing trial)
- Gender: 9M:10F (one dropout), Age range 18-60 years, mean age 47
- All patients had asthma
- Inclusion criteria-stable asthma defined by oral steroid use
- Variation in PEF of > 20% or > 15% FEV1 reversibility after 0.2mg salbutamol delivered by spacer
### Larsen 1994 (Continued)

| Interventions | Home-based  
|               | Ionised air versus control/  
|               | non-ionised air 24 hours per day, Positive or negative not stated  
|               | Ionised air for 4 weeks then control air for 4 weeks  
| Outcomes      | Morning/evening PEF, FEV1, FVC, VC, Symptom scores  
| Notes         | Jadad score: 5  
|               | Higher scoring due to extra information provided by author through personal communication  

#### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>Sealed envelope; investigators unaware as to treatment group assignment</td>
</tr>
</tbody>
</table>

### Lipin 1984

| Methods | Crossover study  
|         | Randomisation method: unclear  
|         | Blinding: double-blind  
|         | Withdrawals: none stated  
|         | Baseline statistics: comparable  
|         | Power calculation: not given  
|         | Jadad score: 3  
| Participants | Total = 12 (12 completing trial)  
|             | Gender: 7M:5F, Age range 9-15 years, mean age 12 years  
|             | All patients were asthmatic  
|             | Inclusion/exclusion criteria-not stated  
|             | No details of severity were reported.  
| Interventions | Laboratory-based study: Positively ionised air versus control/non-ionised air  
|               | 10 minutes exposure and exposure during 6 minute exercise test. Tests carried out 24 hours apart  
| Outcomes      | Bronchial reactivity-  
|               | measuring the effect on FEV1  
| Notes         |  

#### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
</table>
### Lipin 1984 (Continued)

<table>
<thead>
<tr>
<th>Allocation concealment?</th>
<th>Unclear</th>
<th>Information not available</th>
</tr>
</thead>
</table>

### Nogrady 1983

#### Methods
- Crossover study
- Randomisation method: unclear
- Blinding: double-blind
- Excluded: not stated
- Withdrawals: 1
- Power calculation: not given
- Jadad score: 3

#### Participants
- Original version of study had a total no. = 20 adult (19 completing trial).
- Gender: 10M:9F Mean age 36 years
- Original study group of 20 separated into groups (a) and (b) because of gender distribution between groups and baseline lung function higher probably due to gender distribution
- All patients had asthma
- Inclusion/exclusion criteria-not stated
- Group (a) consists of 10 subjects: 8 males and 2 females, which started study on the active ioniser and whose mean (SD) baseline characteristics were:
  - am PEF: 399(132)
  - pm PEF: 442(103)
  - symptom score: 1.8(1.85)
  - medication: 5.9(2.9)
- See Nogrady (b)

#### Interventions
- Home-based
- Negatively ionised air or control/
- non-ionised air. 2 x 8 week treatment arms with 4 weeks washout. Total length of trial 6 months

#### Outcomes
- Morning PEF measurement; Sympton scores

#### Notes

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>Information not available</td>
</tr>
</tbody>
</table>
### Warner 1993

#### Methods
- Crossover study
- Randomisation method: unclear
- Blinding: double-blind
- Excluded: not stated
- Withdrawals: not described
- Baseline characteristics: comparable
- Power calculation: not given
- Jadad score: 3

#### Participants
- Total = 20 (20 completing the trial)
- No gender ratio given.
- Age range 3-11 years, median age 9 years
- All patients had asthma
- Inclusion criteria-Der p1 concentration in the living room and child's bedroom > 2mg/m3 air
- No details of severity reported.

#### Interventions
- Home-based
- Negatively Ionised air versus non-ionised air/ control air. 6 weeks ionised, 6 weeks non-ionised/control.
- Air sampling performed at beginning, middle and end of each period

#### Outcomes
- Morning/evening PEF, nighttime wheeze, daytime wheeze, nighttime cough, daytime cough, daytime activity, medication

#### Notes

<table>
<thead>
<tr>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item</td>
</tr>
<tr>
<td>Allocation concealment?</td>
</tr>
</tbody>
</table>

#### Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jones 1976</td>
<td>Not randomised</td>
</tr>
<tr>
<td></td>
<td>No control group</td>
</tr>
<tr>
<td>Kirkham 1984</td>
<td>Not randomised</td>
</tr>
<tr>
<td>Mitchell 1980</td>
<td>No placebo treatment</td>
</tr>
<tr>
<td></td>
<td>Not blinded</td>
</tr>
<tr>
<td>Nogrady 1983b</td>
<td>Secondary report of included study [Nogrady(a) and Nogrady(b)] No extra data extracted</td>
</tr>
<tr>
<td>Osterballe 1979</td>
<td>Not randomised</td>
</tr>
</tbody>
</table>
Palti 1966 | Groups not comparable. One group of 13 suffering from asthmatic bronchitis. One group of 6 with no respiratory problems
---|---
Ponomarenko 2003 | Study inadequately described to determine whether it was randomised or not
Wickman 1989 | Randomised control trial measuring the ionisers effect on the reduction of airborne particles. Correspondence with author revealed no patient data as none was originally recorded
Zylberberg 1960 | No placebo group
| Compared negative ionisation with positive ionisation
Comparison 1. Negative ionised air versus non-ionised air

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 FEV1 (Fall %) after exercise test</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>1.1 Adults</td>
<td>0</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>1.2 Children</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>2 Baseline FEV1(litres) (after inhalation of negative ions prior to exercise testing)</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>2.1 Adults</td>
<td>0</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>2.2 Children</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>3 Morning Peak Expiratory Flow (Litres/min)</td>
<td>3</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>3.1 Adults</td>
<td>2</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>3.2 Children</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>4 FEV1 (Litres/min) &gt; 4 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>4.1 Adults</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>4.2 Children</td>
<td>0</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>5 Evening Peak Expiratory Flow (Litres/min)</td>
<td>3</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>5.1 Adults</td>
<td>2</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>5.2 Children</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>6 FEV1 (Fall %) after histamine challenge</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>6.1 Adults</td>
<td>0</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>6.2 Children</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>7 Asthma Symptom Score 1</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>7.1 nighttime wheeze</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>7.2 daytime wheeze</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>7.3 nighttime cough</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>7.4 daytime activity</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>8 Asthma Symptom Score 2</td>
<td>2</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>8.1 sleep disturbance</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>8.2 wheeze</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>8.3 activity level</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>8.4 coughing</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>8.5 sputum production</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>8.6 TOTAL</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>8.7 mean score of all five dimensions</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>9 Bronchodilator use</td>
<td>3</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>9.1 Adults</td>
<td>2</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>9.2 Children</td>
<td>1</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>10 Morning PEFR (First arm change score)</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
</tbody>
</table>
Comparison 2. Positive ionised air versus non-ionised air

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 FEV1 (Fall %) after exercise test</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.1 Adults</td>
<td>0</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>1.2 Children</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>2 Baseline FEV1(litres) (after inhalation of positive ions prior to exercise testing)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.1 Adults</td>
<td>0</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>2.2 Children</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
</tr>
</tbody>
</table>

Analysis 1.1. Comparison 1 Negative ionised air versus non-ionised air, Outcome 1 FEV1 (Fall %) after exercise test.

Review: Ionisers for chronic asthma

Comparison: 1 Negative ionised air versus non-ionised air

Outcome: 1 FEV1 (Fall %) after exercise test

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Non-ionised air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ben-Dov 1983</td>
<td>11 21 (9.9)</td>
<td>11 29 (16.6)</td>
<td>-8.00 [-19.42, 3.42]</td>
<td></td>
</tr>
</tbody>
</table>

-100 -50 0 50 100
Favours ionised air Favours control air
Analysis 1.2. Comparison 1 Negative ionised air versus non-ionised air, Outcome 2 Baseline FEV1 (litres) (after inhalation of negative ions prior to exercise testing).

Review: Ionisers for chronic asthma

Comparison: 1 Negative ionised air versus non-ionised air

Outcome: 2 Baseline FEV1 (litres) (after inhalation of negative ions prior to exercise testing)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Control air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ben-Dov 1983</td>
<td>11</td>
<td>1.35 (0.26)</td>
<td>11</td>
<td>1.37 (0.23)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-0.02 [-0.23, 0.19]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Analysis 1.3. Comparison 1 Negative ionised air versus non-ionised air, Outcome 3 Morning Peak Expiratory Flow (Litres/min).

Review: Ionisers for chronic asthma

Comparison: 1 Negative ionised air versus non-ionised air

Outcome: 3 Morning Peak Expiratory Flow (Litres/min)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Non-ionised air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larsen 1994</td>
<td>19</td>
<td>354.9 (123.7)</td>
<td>9</td>
<td>357.8 (137.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2.90 [-108.78, 102.98]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nogrady 1983</td>
<td>10</td>
<td>403 (120)</td>
<td>10</td>
<td>416 (121)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-13.00 [-118.62, 92.62]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warner 1993</td>
<td>20</td>
<td>232.6 (87.5)</td>
<td>20</td>
<td>231.3 (96.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.30 [-55.79, 58.39]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 1.4. Comparison 1 Negative ionised air versus non-ionised air, Outcome 4 FEV1 (Litres/min) > 4 weeks.

**Review:** Ionisers for chronic asthma

**Comparison:** Negative ionised air versus non-ionised air

**Outcome:** FEV1 (Litres/min) > 4 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Non-ionised air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larsen 1994</td>
<td>19</td>
<td>2.38 (1.1)</td>
<td>19</td>
<td>2.47 (0.95)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-0.09 [-0.74, 0.56]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

-4 -2 0 2 4

Favours control air  Favours ionised air

### Analysis 1.5. Comparison 1 Negative ionised air versus non-ionised air, Outcome 5 Evening Peak Expiratory Flow (Litres/min).

**Review:** Ionisers for chronic asthma

**Comparison:** Negative ionised air versus non-ionised air

**Outcome:** Evening Peak Expiratory Flow (Litres/min)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Non-ionised air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larsen 1994</td>
<td>19</td>
<td>372 (125.2)</td>
<td>19</td>
<td>378.7 (139.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-6.70 [-91.05, 77.65]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nogrady 1983</td>
<td>10</td>
<td>435 (103)</td>
<td>10</td>
<td>454 (115)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-19.00 [-114.69, 76.69]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warner 1993</td>
<td>14</td>
<td>239.2 (91.67)</td>
<td>14</td>
<td>232.8 (97.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6.40 [-63.78, 76.58]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

-100 -50 0 50 100

Favours control air  Favours ionised air

---

**Ionisers for chronic asthma (Review)**

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Analysis 1.6. Comparison 1 Negative ionised air versus non-ionised air, Outcome 6 FEV1 (Fall %) after histamine challenge.**

Review: Ionisers for chronic asthma

Comparison: Negative ionised air versus non-ionised air

Outcome: 6 FEV1 (Fall %) after histamine challenge

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Non-ionised air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>N</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td>-1.00 [-16.31, 14.31]</td>
<td></td>
</tr>
<tr>
<td>2 Children</td>
<td></td>
<td></td>
<td>-1.00 [-16.31, 14.31]</td>
<td></td>
</tr>
<tr>
<td>Ben-Dov 1983</td>
<td>9</td>
<td>9</td>
<td>-1.00 [-16.31, 14.31]</td>
<td></td>
</tr>
</tbody>
</table>

**Analysis 1.7. Comparison 1 Negative ionised air versus non-ionised air, Outcome 7 Asthma Symptom Score 1.**

Review: Ionisers for chronic asthma

Comparison: Negative ionised air versus non-ionised air

Outcome: 7 Asthma Symptom Score 1

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Control air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>N</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
<td></td>
</tr>
<tr>
<td>nighttime wheeze</td>
<td></td>
<td></td>
<td>-0.01 [-0.22, 0.20]</td>
<td></td>
</tr>
<tr>
<td>Warner 1993</td>
<td>14</td>
<td>14</td>
<td>-0.01 [-0.22, 0.20]</td>
<td></td>
</tr>
<tr>
<td>daytime wheeze</td>
<td></td>
<td></td>
<td>0.02 [-0.20, 0.24]</td>
<td></td>
</tr>
<tr>
<td>Warner 1993</td>
<td>14</td>
<td>14</td>
<td>0.02 [-0.20, 0.24]</td>
<td></td>
</tr>
<tr>
<td>nighttime cough</td>
<td></td>
<td></td>
<td>0.29 [-0.09, 0.67]</td>
<td></td>
</tr>
<tr>
<td>Warner 1993</td>
<td>14</td>
<td>14</td>
<td>0.29 [-0.09, 0.67]</td>
<td></td>
</tr>
<tr>
<td>daytime activity</td>
<td></td>
<td></td>
<td>0.0 [-0.10, 0.10]</td>
<td></td>
</tr>
<tr>
<td>Warner 1993</td>
<td>14</td>
<td>14</td>
<td>0.0 [-0.10, 0.10]</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 1.8. Comparison 1 Negative ionised air versus non-ionised air, Outcome 8 Asthma Symptom Score 2.

**Review:** Ionisers for chronic asthma  
**Comparison:** 1 Negative ionised air versus non-ionised air  
**Outcome:** 8 Asthma Symptom Score 2

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Mean(SD)</th>
<th>Control air</th>
<th>Mean(SD)</th>
<th>Mean Difference IV,Fixed,95% CI</th>
<th>Mean Difference IV,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 sleep disturbance</td>
<td>Larsen 1994</td>
<td>19</td>
<td>9.1 (12.1)</td>
<td>19</td>
<td>5.9 (9.7)</td>
<td>3.20 [-3.77, 10.17]</td>
</tr>
<tr>
<td>3 activity level</td>
<td>Larsen 1994</td>
<td>19</td>
<td>13.7 (17.7)</td>
<td>19</td>
<td>11.6 (15.9)</td>
<td>2.10 [-8.60, 12.80]</td>
</tr>
<tr>
<td>4 coughing</td>
<td>Larsen 1994</td>
<td>19</td>
<td>11.3 (15)</td>
<td>19</td>
<td>8.6 (10.5)</td>
<td>2.70 [-5.53, 10.93]</td>
</tr>
<tr>
<td>5 sputum production</td>
<td>Larsen 1994</td>
<td>19</td>
<td>9.6 (12.8)</td>
<td>19</td>
<td>7.3 (10.6)</td>
<td>2.30 [-5.17, 9.77]</td>
</tr>
<tr>
<td>6 TOTAL</td>
<td>Larsen 1994</td>
<td>19</td>
<td>55.8 (59.9)</td>
<td>19</td>
<td>42.3 (43.34)</td>
<td>13.50 [-19.74, 46.74]</td>
</tr>
<tr>
<td>7 mean score of all five dimensions</td>
<td>Nogrady 1983</td>
<td>10</td>
<td>1.31 (1.49)</td>
<td>10</td>
<td>1.04 (1.42)</td>
<td>0.27 [-1.01, 1.55]</td>
</tr>
</tbody>
</table>

-100 -50 0 50 100  
Favours ionised air  
Favours control air
### Analysis 1.9. Comparison 1 Negative ionised air versus non-ionised air, Outcome 9 Bronchodilator use.

**Review:** Ionisers for chronic asthma

**Comparison:** 1 Negative ionised air versus non-ionised air

**Outcome:** 9 Bronchodilator use

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Non-ionised air</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larsen 1994</td>
<td>19</td>
<td>56.37 (45.69)</td>
<td>19</td>
<td>55.16 (43.9)</td>
</tr>
<tr>
<td>Nogrady 1983</td>
<td>10</td>
<td>5.96 (2.99)</td>
<td>10</td>
<td>5.16 (3.12)</td>
</tr>
<tr>
<td>2 Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warner 1993</td>
<td>14</td>
<td>0.48 (0.67)</td>
<td>14</td>
<td>0.53 (0.94)</td>
</tr>
</tbody>
</table>

### Analysis 1.10. Comparison 1 Negative ionised air versus non-ionised air, Outcome 10 Morning PEFR (First arm change score).

**Review:** Ionisers for chronic asthma

**Comparison:** 1 Negative ionised air versus non-ionised air

**Outcome:** 10 Morning PEFR (First arm change score)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Nogrady 1983</td>
<td>10</td>
<td>3.4 (23.8)</td>
<td>9</td>
<td>-0.78 (24.9)</td>
</tr>
</tbody>
</table>

---

Ionisers for chronic asthma (Review)  
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 2.1. Comparison 2 Positive ionised air versus non-ionised air, Outcome 1 FEV1 (Fall %) after exercise test.

Review: Ionisers for chronic asthma

Comparison: 2 Positive ionised air versus non-ionised air

Outcome: 1 FEV1 (Fall %) after exercise test

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Non-ionised air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  Mean(SD)</td>
<td>N  Mean(SD)</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipin 1984</td>
<td>12</td>
<td>35 (17.3)</td>
<td>-10.00 [ -3.84, 23.84 ]</td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 2.2. Comparison 2 Positive ionised air versus non-ionised air, Outcome 2 Baseline FEV1 (litres) (after inhalation of positive ions prior to exercise testing).

Review: Ionisers for chronic asthma

Comparison: 2 Positive ionised air versus non-ionised air

Outcome: 2 Baseline FEV1 (litres) (after inhalation of positive ions prior to exercise testing)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ionised air</th>
<th>Control air</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  Mean(SD)</td>
<td>N  Mean(SD)</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipin 1984</td>
<td>12</td>
<td>1.64 (0.41)</td>
<td>-0.02 [ -0.35, 0.31 ]</td>
<td></td>
</tr>
</tbody>
</table>
WHAT'S NEW

Last assessed as up-to-date: 18 January 2010.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 January 2010</td>
<td>New search has been performed</td>
<td>Literature search re-run; no new studies.</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 4, 2000

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 August 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
<tr>
<td>1 February 2003</td>
<td>New citation required and conclusions have changed</td>
<td>Substantive amendment</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

KB and SLA developed the protocol with suggested changes from CJC
KB carried out searches and KB and SLA reviewed abstracts for inclusion
KB and SLA extracted data with advice on data entry from CJC
SLA conducted the meta-analysis and reported results
KB wrote the abstract. SLA and KB developed the discussion and conclusion section with CJC.

DECLARATIONS OF INTEREST

None known.
SOURCES OF SUPPORT

Internal sources
  • None, UK.

External sources
  • None, UK.

INDEX TERMS

Medical Subject Headings (MeSH)
  *Air Ionization; Anions [therapeutic use]; Asthma [* therapy]; Cations [therapeutic use]; Ions [* therapeutic use]; Randomized Controlled Trials as Topic

MeSH check words
  Adult; Child; Humans